An investigational induced pluripotent stem cell-derived CAR natural killer cell therapy was well tolerated both as ...
"Be Bio secures $92m for haemophilia B and hypophosphatasia treatments" was originally created and published by ...
A new type of cell-based immunotherapy shows promise for B-cell lymphomas, and due to innovations in manufacturing, could ...
A phase 1 clinical trial co-led by researchers at Washington University School of Medicine in St. Louis found that a new type ...
Patients with relapsed or refractory large B-cell lymphoma who received epcoritamab or glofitamab in real-world settings ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received 510(k) clearance from the United States Food and Drug ...
Rese-cel, previously called CABA-201, is a CAR T-cell therapy that's designed to treat MS by depleting B-cells.
Roche (RHHBY) said Monday that it has received 510(k) clearance from the U.S. Food and Drug Administration for its highly-sensitive ...
A new type of cell-based immunotherapy shows promise for B-cell lymphomas and - due to innovations in manufacturing - could make future cellular immunotherapies less expensive and more accessible to ...
Roche (RHHBY) announced that it has received 510(k) clearance from the FDA for its highly-sensitive in-situ hybridisation test, the Ventana ...